Examining a patient for common or complex pulmonary issues in a primary care setting takes time and expertise — physicians need to ask about symptoms and medical history and determine which tests to ...

Having stacked all its chips on the idiopathic pulmonary fibrosis (IPF) treatment buloxibutid, Vicore Pharma’s bet may be paying off. The Swedish biotech has unveiled final phase 2a data showing the ...

A new drug to alleviate idiopathic pulmonary fibrosis, a condition where the lungs harden and make breathing difficult, has emerged after 10 years. The U.S. Food and Drug Administration, FDA, recently ...

The study, titled “Structural and Functional Pulmonary MRI to Predict Pulmonary Exacerbations in Cystic Fibrosis,” analyzed imaging and clinical data from 106 individuals with CF who were imaged and ...

Please provide your email address to receive an email when new articles are posted on . Pulmonary function testing results can indicate obstructive patterns. Providers must properly coach patients ...

The use of newly developed race-neutral reference equations for pulmonary function test (PFT) interpretation led to a significant increase in both the prevalence and severity of respiratory ...

A drug prototype known as NZ-97 showed promise for treating pulmonary disease by stimulating growth of new stem cells to repair damaged tissue, based on data from a new proof-of-concept study. In many ...

Pulmonary sarcoidosis is a condition that causes tiny groups of immune cells to clump in your lungs. These groups of cells form swollen, inflamed lumps called granulomas. Granulomas can make it hard ...